Secretome-Derived MSCs Attenuate VEGF and p38 Gene Expression in a PCOS Mouse Model: Implications for Therapeutic Interventions

Background: Polycystic Ovary Syndrome (PCOS) is the highest cause of infertility in women of reproductive age. Regardless of the incidence, handling and providing therapy for PCOS is very limited and based on symptom management. MSCs can secrete a secretome containing anti-inflammatory cytokines such as IL-10, reducing the inflammatory process and improving ovarian function. Objective: To prove the effect of SH-MSCs administration on VEGF and p38 gene expression in PCOS rat models. Method: In vivo experimental research with a post-test-only control group design. The total sample was 24 Wistar female rats divided into four groups. Group K1 (healthy mice), group K2 (PCOS mice were injected with 0.9% NaCl), group K3 (PCOS mice were given a dose of 200 µl Secretome), and group K4 (PCOS mice were given a 400 µl dose of Secretome) and were treated for 33 days. PCR results of VEGF and P38 gene expression were tested using the One-Way ANOVA test followed by the Post Hoc LSD test. Results: The expression of VEGF and P38 gene was different in K4-K2 sig. (p<0.05) and there was a difference in the expression of VEGF and P38 gene in K3-K2 sig. (p<0.05), and the expression of the VEGF and P38 gene showed a decreasing trend in the K4-K3 after treatment. Conclusion: SH-MSCs reduced the expression of the VEGF gene and the P38 gene in PCOS.